

Aduro BioTech announces interim Phase 1B clinical data of CRS-207 for the treatment of mesothelioma accepted for oral presentation at the International Mesothelioma Interest Group conference

October 15, 2014 4:45 PM ET

October 15, 2014 04:00 PM Eastern Daylight Time

BERKELEY, Calif. -- Aduro BioTech, Inc., a leader in cancer immunotherapy, today announced that interim data from the Phase 1B clinical trial of its CRS-207 cancer immunotherapy in combination with chemotherapy as a front line treatment for malignant pleural mesothelioma will be presented at the International Mesothelioma Interest Group (iMig) Conference to be held in Cape Town, South Africa, October 21-24, 2014.

The data will be presented by Raffit Hassan, M.D., co-chief of the Thoracic and GI Oncology Branch at the National Cancer Institute. Details of the presentation are as follows:

- Title: Anti-mesothelin Vaccine CRS-207 Plus Chemotherapy as Front-Line Treatment for Malignant Pleural Mesothelioma (MPM)
- Presenter: Raffit Hassan, M.D., co-chief of the Thoracic and GI Oncology Branch at the National Cancer Institute
- Session: Immunotherapy
- Date: Wednesday, October 22, 2014
- Time: 10:30 a.m. Local Time

About CRS-207

CRS-207 is one of a family of product candidates based on Aduro's live-attenuated, double-deleted (LADD) *Listeria monocytogenes* immunotherapy platform that induce a potent innate and T cell-mediated immune response. CRS-207 has been engineered to express the tumor-associated antigen mesothelin, which is over-expressed in many cancers including mesothelioma, pancreatic, non-small cell lung, ovarian and gastric cancers.

About Malignant Pleural Mesothelioma

Mesothelioma is a form of cancer that affects the smooth layer of mesothelial cells that surround the chest, lungs, heart and abdomen. Malignant pleural mesothelioma (MPM), which affects the thin balloon shaped lining of the lungs, is the most common form of this disease and accounts for around 2,500 cases a year in the United States. MPM is an aggressive disease with a poor prognosis. Most MPM patients are not candidates for surgical resection. Based on prior studies, expected median progression-free survival is 5.7 months and overall survival is 12.1 months with combination pemetrexed and cisplatin chemotherapy. The tumor-associated antigen mesothelin is overexpressed in virtually all cases of mesothelioma.

About Aduro BioTech, Inc.

Aduro BioTech, Inc. is a private, clinical-stage biotechnology company focused on immunotherapy for cancer. Aduro has ongoing clinical trials with its LADD platform in pancreatic cancer, mesothelioma and high-grade glioma and its immunotherapies are in development in non-small cell lung cancer, ovarian cancer and prostate cancer. The company is also developing clinical candidates using novel small molecules that activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit www.adurobiotech.com.

Contacts

Aduro BioTech
Greg W. Schafer, 510-809-4801
Chief Operating Officer

or

Media Contact:

Angela Bitting, 925-202-6211

a.bitting@comcast.net